Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment o
- PDF / 806,777 Bytes
- 15 Pages / 595.276 x 790.866 pts Page_size
- 78 Downloads / 164 Views
ORIGINAL RESEARCH
Evaluating the Long-Term Cost-Effectiveness of OnceWeekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK Pierre Johansen
. Barrie Chubb . Barnaby Hunt . Samuel J. P. Malkin .
Anna Sandberg . Matthew Capehorn
Received: February 20, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Once-weekly semaglutide 1 mg is a novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes that has demonstrated significantly greater reductions in glycated haemoglobin (HbA1c) and body weight than the GLP-1 RA once-daily liraglutide 1.2 mg in the SUSTAIN 10 trial. The present analysis aimed to evaluate the longterm cost-effectiveness of once-weekly semaglutide 1 mg versus once-daily liraglutide 1.2 mg from a UK healthcare payer perspective. Methods: Long-term outcomes were projected using the IQVIA CORE Diabetes Model (version 9.0), with baseline characteristics and treatment effects sourced from SUSTAIN 10. Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12063384. Electronic Supplementary Material The online version of this article (https://doi.org/10.1007/s12325020-01337-7) contains supplementary material, which is available to authorized users. P. Johansen (&) B. Chubb A. Sandberg Novo Nordisk A/S, Søborg, Denmark e-mail: [email protected] B. Hunt S. J. P. Malkin Ossian Health Economics and Communications GmbH, Basel, Switzerland M. Capehorn Rotherham Institute for Obesity, Rotherham, UK
Patients were assumed to initiate treatment with GLP-1 RAs and continue treatment until HbA1c exceeded 7.5%, at which point GLP-1 RAs were discontinued and basal insulin was initiated. Pharmacy costs and costs of complications were measured in 2018 pounds sterling (GBP), with future costs and outcomes discounted at 3.5% per annum. Utilities were taken from published sources. Results: In the base-case analysis, once-weekly semaglutide 1 mg was associated with an increase in discounted life expectancy of 0.21 years and discounted quality-adjusted life expectancy of 0.30 quality-adjusted life-years, compared with once-daily liraglutide 1.2 mg. Clinical benefits were achieved at reduced costs, with lifetime cost savings of GBP 140 per patient with semaglutide versus liraglutide, owing to a reduction in diabetes-related complications, in particular cardiovascular disease (mean cost saving of GBP 279 per patient). Therefore, once-weekly semaglutide 1 mg was dominant compared with once-daily liraglutide 1.2 mg. The results of the sensitivity analyses were similar, demonstrating the robustness of the base-case analysis. Conclusions: Once-weekly semaglutide 1 mg is a cost-effective treatment option versus oncedaily liraglutide 1.2 mg, based on the SUSTAIN 10 trial, from a UK healthcare payer perspective.
Adv Ther
Keywords: Cost-effectiveness; Diabetes; Economic evaluation; Glucagon-like peptide-1 receptor agonists; Liraglutide; Semaglutide; Type 2 diabetes Key Summary Points Why carry out this s
Data Loading...
